VEGFA and systemic sclerosis: The potential role of these angiogenic circulating and inflammatory biomarkers in SSc screening is supported by numerous clinical studies, which have shown high levels of soluble vascular endothelial growth factor (VEGF) receptor 1 (sVEGFR1) [78,79] in patients predisposed to the development of PAH [80].